Total Funding
15
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-35 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Cmxtwenty focuses on developing lipid compounds for use in non-narcotic pain treatment.
Lane Brostrom: Chairman and Chief Executive Officer
About the Company
Cmxtwenty is a Milwaukee based pharmaceutical company focused on the development of a unique lipid compound to be used as a non-narcotic treatment for pain.
Established in November 2004, Cmxtwenty received its initial funding through an SBIR grant from the National Institute on Drug Abuse (NIDA). Since 2007, Cmxtwenty has been funded privately by
a network of individual investors. Their lead product, CMX-020, is an analog of arachidonic acid, a common endogenous lipid and one of the most abundant lipids for cell signaling in the brain. Cmxtwenty maintains international patent filings on CMX-020 through 2029. Phase 1 clinical studies are currently ongoing.
